Elberon Lowers stake in BioScrip Inc (BIOS)

BioScrip Inc (BIOS) : Elberon reduced its stake in BioScrip Inc by 30.64% during the most recent quarter end. The investment management company now holds a total of 2,334,000 shares of BioScrip Inc which is valued at $6,371,820 after selling 1,031,000 shares in BioScrip Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.BioScrip Inc makes up approximately 10.43% of Elberon’s portfolio.

Other Hedge Funds, Including , Wynnefield Capital Inc boosted its stake in BIOS in the latest quarter, The investment management firm added 725,000 additional shares and now holds a total of 2,175,000 shares of BioScrip Inc which is valued at $5,937,750. BioScrip Inc makes up approx 1.97% of Wynnefield Capital Inc’s portfolio.Alliancebernstein boosted its stake in BIOS in the latest quarter, The investment management firm added 12,400 additional shares and now holds a total of 94,100 shares of BioScrip Inc which is valued at $256,893.Roanoke Asset Management Corp Ny boosted its stake in BIOS in the latest quarter, The investment management firm added 112,325 additional shares and now holds a total of 277,020 shares of BioScrip Inc which is valued at $723,022. BioScrip Inc makes up approx 0.32% of Roanoke Asset Management Corp Ny’s portfolio. South Texas Money Management Ltd sold out all of its stake in BIOS during the most recent quarter. The investment firm sold 63,032 shares of BIOS which is valued $164,514.

BioScrip Inc closed down -0.01 points or -0.39% at $2.57 with 2,41,484 shares getting traded on Thursday. Post opening the session at $2.57, the shares hit an intraday low of $2.51 and an intraday high of $2.6 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, BioScrip Inc reported $-0.14 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.09. The company had revenue of $232.50 million for the quarter, compared to analysts expectations of $227.52 million. The company’s revenue was down -11.4 % compared to the same quarter last year.

BioScrip Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians hospital systems skilled nursing facilities healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy respiratory therapy and the provision of durable medical equipment products and services. Its PBM Services segment consists of integrated PBM services which primarily consists of discount card programs that provide alternative for individuals who may be uninsured underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products services and condition-specific clinical management programs for health conditions such as gastrointestinal abnormalities infectious diseases and others.

Leave a Reply

BioScrip Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioScrip Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.